Get the Stockscreener App
10.10
2.42%
-0.25
After Hours:
10.30
0.20
+1.98%
Nuvectis Pharma Inc stock is traded at $10.10, with a volume of 127.60K.
It is down -2.42% in the last 24 hours and up +13.48% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$10.35
Open:
$10.5
24h Volume:
127.60K
Relative Volume:
1.73
Market Cap:
$267.91M
Revenue:
-
Net Income/Loss:
$-28.87M
P/E Ratio:
-7.866
EPS:
-1.284
Net Cash Flow:
$-16.01M
1W Performance:
-1.94%
1M Performance:
+13.48%
6M Performance:
+66.67%
1Y Performance:
+2.75%
1-Day Range:
$10.00
$10.73
1-Week Range:
$10.00
$11.40
52-Week Range:
$5.55
$13.34
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
10.10 | 274.54M | 0 | -28.87M | -16.01M | -1.284 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Wall Street analysts think Nuvectis Pharma (NVCT) could surge 57%: Read this before placing a bet - MSN
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet - sharewise.com
Nuvectis Pharma (NVCT) Surges +2.82%, Nearing $11.48 Resistance 2026-05-21Low Volatility Picks - Newser
Understanding the Setup: (NVCT) and Scalable Risk - Stock Traders Daily
NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma set to participate in key investor event at NASDAQ - Traders Union
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor ... - Caledonian Record
Number of shareholders of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Number of shareholders of Nuvectis Pharma, Inc. – BOATS:NVCT - TradingView
TradingKey - TradingKey
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN
Nuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66 - MSN
The Technical Signals Behind (NVCT) That Institutions Follow - Stock Traders Daily
What Nuvectis Pharma (NVCT) does that creates lasting value (Creeps Higher) 2026-05-08Momentum Investing - newser.com
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth - simplywall.st
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvectis Pharma | 10-Q: Q1 2026 Earnings Report - Moomoo
Nuvectis Pharma, Inc. Q1 2026: Net loss $(6.05M), EPS $(0.26) — 10-Q Summary - TradingView
Nuvectis Pharma (NASDAQ: NVCT) posts $6.1M Q1 loss with $25.1M cash - Stock Titan
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsSEC.gov - SEC.gov
Nuvectis Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nuvectis Pharma posts first quarter 2026 financial results and business update - Traders Union
Cancer drug developer targets summer data as cash drops to $25.1M - Stock Titan
Nuvectis Pharma reports Q1 2026 loss of $6.1M, advances NXP900 cancer drug trials with data expected in summer. - Pluang
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma - Yahoo Finance
NVCT (Nuvectis Pharma) posts narrow Q4 2025 EPS miss, edging down 0.23% in muted investor reaction.Open Stock Picks - newser.com
Nuvectis Pharma Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
NVCT Forecast, Price Target & Analyst Ratings | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma (NVCT) Stock: Technical Risk Signals | Q4 2025: Below ExpectationsCommunity Risk Signals - Newser
Nuvectis Pharma (NVCT) Projected to Post Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ: NVCT) details 2026 annual meeting and executive pay - Stock Titan
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
NVCT (Nuvectis Pharma) posts slight Q4 2025 EPS miss, yet shares edge higher on positive investor sentiment.Convertible Notes - Newser
Technical Reactions to NVCT Trends in Macro Strategies - Stock Traders Daily
Nuvectis Pharma, Inc. $NVCT Shares Acquired by Iridian Asset Management LLC CT - MarketBeat
Will Nuvectis Pharma (NVCT) Stock Recover Soon | Price at $7.65, Up 1.19%Equal Weight ETF - Newser
Trading the Move, Not the Narrative: (NVCT) Edition - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Trading Down 1.7%Here's What Happened - MarketBeat
Nuvectis to present NXP900 data at cancer research meeting By Investing.com - Investing.com South Africa
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting - Investing News Network
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):